# A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor

> **NCT07000344** · NA · TERMINATED · sponsor: **Peking Union Medical College Hospital** · enrollment: 5 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Cohort 1 (triple-drug group)
- **DRUG:** Cohort 2 (dual-drug group)

## Key facts

- **NCT ID:** NCT07000344
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-07-01
- **Primary completion:** 2026-03-29
- **Final completion:** 2026-03-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Results failed to achieve the anticipated effect.
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000344, "A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07000344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*